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Abstract
Regenerative medicine is an exciting field that aims to create regenerative alternatives to
harvest tissues for transplantation. In this approach, the delivery of cells and biological
molecules plays a central role. The scaffold (synthetic temporary extracellular matrix) delivers
cells to the regenerative site and provides three-dimensional environments for the cells.
To fulfil these functions, we design biodegradable polymer scaffolds with structural features
on multiple size scales. To enhance positive cell–material interactions, we design nano-sized
structural features in the scaffolds to mimic the natural extracellular matrix. We also integrate
micro-sized pore networks to facilitate mass transport and neo tissue regeneration. We also
design novel polymer devices and self-assembled nanospheres for biomolecule delivery to
recapitulate key events in developmental and wound healing processes. Herein, we present
recent work in biomedical polymer synthesis, novel processing techniques, surface
engineering and biologic delivery. Examples of enhanced cellular/tissue function and
regenerative outcomes of these approaches are discussed to demonstrate the excitement of the
biomimetic scaffold design and biologic delivery in regenerative medicine.
Keywords: biomaterials, nanomaterials, tissue engineering, regenerative medicine, scaffold,
controlled release, biodegradable polymer
1. Introduction to polymers in regenerative medicine
Biocompatible polymers have played an integral role in tissue
engineering, especially within the realm of scaffold design
[1, 2]. These materials are chosen based on their acceptance in
the body environment and their ability to biodegrade at a rate
comparable to the rate of tissue regeneration. Of the multiple
polymeric materials used for tissue engineering, some are
naturally derived, including collagen, gelatin and chitosan,
and many more are synthetic, including polyethylene oxide
(PEO), polyvinyl alcohol (PVA), poly(lactic acid) (PLA)
and poly(glycolic acid) (PGA), and copolymers of the two
(PLGA).
Naturally derived polymers are limited in supply and
can therefore be costly, while synthetic polymers are widely
available and have been broadly used in the design of
scaffolds for various tissue engineering applications. PLA,
PGA, and their copolymer are the most commonly used
synthetic polymers that degrade through hydrolysis into
non-toxic products. Poly(L-lactic acid) (PLLA) in particular
is a synthetic polymer which can be readily manipulated
into thin films, micro- and nano-fibers, porous scaffolds,
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three-dimensional fibrous networks and other complex
geometries, making it a good candidate as a material for
scaffold fabrication.
Our group has developed multiple techniques for forming
highly porous biodegradable polymer and polymer/apatite
composite scaffolds with various geometries conducive to
cell differentiation and bone tissue regeneration. This review
showcases some of these results, in which polymer scaffolds
are designed to positively affect cell differentiation and
ultimately lead to new tissue formation. This is done by
mimicking the structural components of the extracellular
matrix, as well as through using the scaffold as a vehicle for
the delivery of biologic agents to aid in bone formation.
2. The scaffold as a temporary extracellular matrix
The extracellular matrix (ECM) is a model used for
inspiration when designing biomimetic scaffolds for tissue
engineering [3]. By mimicking the structure and/or surface
properties of the naturally occurring ECM, engineers may
be able to influence cell growth and tissue formation. The
features shared by the ECM and these scaffolds act to promote
cell attachment and proliferation and provide biological cues
to the cells.
The collagen fibers present in the bone ECM are between
50 and 500 nm in diameter. These fibers act as a foundation,
onto which osteoblasts deposit apatite crystals during bone
formation. It is widely hypothesized that this fibrous construct
may play an important role in regulating cell behavior and
subsequent tissue growth. Much work in biomimetic scaffold
design has focused on maintaining and improving upon
these features by more effectively mimicking the natural
ECM [4].
Another way in which this is being done is by creating
biomimetic composite scaffolds, which incorporate a ceramic
component into the polymer network. For example, by
combining a polymer with hydroxyapatite (HA), we can study
the mineralization of the ECM collagen creating a scaffold
that mimics those mineralized collagen fibers.
3. Nano-scale engineering and scaffold design
The fabrication of nano-fibers that mimic the collagen
present in the natural ECM is approached in three ways.
These are electrospinning, molecular self-assembly and phase
separation. Each method follows a different path to the
end product, with different results. Electrospinning has been
used to fabricate fibers from both natural macromolecules
and synthetic biodegradable polymers [5–12]. Self-assembly
is a method by which individual molecules organize
spontaneously into a well-defined and stable hierarchical
structure [13–15]. The first two methods can both successfully
yield fibers within the range of collagen fibers [16], but
do not generate a well-defined macropore structure. Phase
separation, on the other hand, has generated nano-fibers
(figure 1) in the same range as natural extracellular matrix
collagen and allows for the inclusion of these more-complex
structural elements [17–19]. An artificial extracellular matrix
(a)
(b)
Figure 1. Scanning electron micrograph of nano-fibrous PLLA
scaffold, prepared from 2.5% (w/v) PLLA/THF solution at a
gelation temperature of 8 ◦C: (a) image at a low magnification;
(b) image at a high magnification (reprinted with permission
from [18] ©1999 John Wiley and Sons Inc.).
with an interconnected pore structure has the potential to
accommodate cells, provide nutrient transport and guide
growth and subsequent tissue regeneration.
A biomimetic approach has been developed in which
partially carbonated hydroxyapatite is grown onto previously
fabricated, porous, polymer scaffolds using simulated body
fluid (SBF) treatment [20]. To improve this biomimetic
process, various materials and processing parameters have
been investigated to determine which combination leads to
ideal apatite formation [21]. This work is ongoing, but poly
(L-lactide) scaffolds treated with SBF yielded a uniform
distribution of apatite particles, and are therefore a system of
interest (figure 2) [19].
4. Cell response to nano-engineered scaffolds
Three-dimensional nano-fibrous scaffolds resulted in
improved protein adsorption, an important part of the
cell/surface interaction. This is not surprising, since it is
known that the interaction of collagen fibers with integrins
signals the expression of osteoblast phenotype genes such
as osteocalcin (OCN) and bone sialoprotein (BSP) [22, 23].
Scaffolds with nano-fibrous pore walls adsorbed four times
more serum proteins than scaffolds with solid pore walls
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Figure 2. Scanning electron micrographs of nano-fibrous
PLLA/HA scaffold treated in SBF for (a) 4 days and (b) 8 days
(reprinted with permission from [19] ©2006 John Wiley and Sons
Inc.).
and selectively enhanced the adsorption of fibronectin and
vitronectin. Additionally, nano-fibrous scaffolds led to a
greater than 1.7-fold increase in osteoblastic cell attachment
compared to solid-walled scaffolds [24]. In a separate
study, biomineralization was enhanced substantially on the
nano-fibrous scaffolds compared to solid-walled scaffolds,
and this was confirmed by von Kossa staining, measurement
of calcium contents and scanning electron microscopy
(figure 3) [25]. In support of this finding, osteoblasts cultured
on the nano-fibrous scaffolds exhibited higher alkaline
phosphatase activity and an earlier and enhanced expression
of the osteoblast phenotype versus solid-walled scaffolds.
These results demonstrate that a biomimetic scaffold
incorporating a nano-fibrous architecture has great potential
for tissue engineering.
Compared with solid-walled scaffolds, nano-fibrous
scaffolds supported substantially more new bone tissue
formation in vivo. This was verified by micro-computed
tomography measurement, von Kossa, Goldner’s trichrome,
Runx2 and bone sialoprotein (BSP) staining [26].
Composite scaffolds of PLLA/HA led to improvement in
cell survival over plain PLLA scaffolds [27]. This is due to the
fact that PLLA/HA scaffolds adsorbed 1.4 times the amount of
serum protein and higher levels of fibronectin and vitronectin
compared to PLLA controls, demonstrating that composite
scaffolds are advantageous for bone tissue engineering.
Multiple non-chemical factors have a role in tissue




Figure 3. Scanning electron microscope views of neonatal mouse
osteoblasts on (a) solid-walled scaffold and (b, c) nano-fibrous
scaffolds (reprinted with permission from [25] ©2007 Elsevier Ltd).
an important part of bone development. By mimicking the
physical features of the ECM, our group has been able to
positively affect cell differentiation leading to subsequent
tissue formation. To date, our nano-fibrous matrices have
led to improved cellular behavior including osteoblastic
cell morphology, cytoskeleton and adhesion structure,
proliferation and differentiation versus flat films [28], mouse
embryonic stem cell (ESC) differentiation and mineralization
versus flat films and thin fibrous constructs [29],
rhBMP-7 induced human amniotic fluid-derived stem cell
(hAFSC) differentiation versus solid-walled scaffolds [30],
human bone marrow-derived mesenchymal stem cells
(hMSCs) development along osteogenic and chondrogenic
routes [31].
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Figure 4. Scanning electron microscope views of
nano-fibrous/macroporous PLLA scaffold incorporating PLGA
microspheres (reprinted with permission from [41] ©2007 Elsevier
Ltd).
5. Biomolecule delivery
The potential of using biodegradable polymer scaffolds
as a vehicle for biologic factor delivery has been widely
investigated by our group and others. Two basic approaches
have been used to this point. The first is to directly
incorporate the factors into the biodegradable scaffold
itself, so that as biodegradation proceeds, the agent is
released [32–34]. The second approach is to incorporate either
micro- or nano-spheres of degradable polymers with defined
degradation rates, incorporated with the given factor, into the
scaffold. These spheres then degrade, releasing the agent into
the biologic environment in a controlled fashion [35–37].
The first method was used with bFGF incorporated
into a synthetic polymer matrix used as delivery devices
for hepatocyte transplantation [38]. Implantation of these
devices increases angiogenesis into the device and increases
hepatocyte engraftment. For example, specimens from the
bFGF group showed a 2.5-fold increase in hepatocyte
engraftment as compared with the control group. Similarly,
the incorporation of bFGF in gelatin matrix also enhanced
bone regeneration [39].
The second method has been investigated by our group
for its ability to better control protein release [40]. The
results illustrate the feasibility of achieving local delivery
of proteins by a microsphere encapsulation technique.
A bone morphogenetic protein (rhBMP-7) was released from
nano-sphere-immobilized nano-fibrous scaffolds (figure 4)
and actively induced new bone formation [41].
Similarly, platelet-derived growth factor-BB (PDGF-BB)
was released from PLGA microspheres in PLLA nano-fibrous
scaffolds [42]. Sustained release was controlled through
differing the molecular weight of the microspheres. The
released PDGF-BB maintained its biological activity. PLGA
microspheres in nano-fibrous scaffolds have been shown to
control the release of rhPDGF-BB in vitro and were assessed
in vivo in a soft tissue wound repair model in rats [43].
The percentage of tissue invasion into microsphere-containing
scaffolds was higher in the PDGF groups when compared to
controls.
6. Moving forward
Tissue engineered scaffolds can serve as vehicles for the
delivery of cells to the regeneration site in vivo. Nano-scale
engineering of scaffold architecture is utilized to mimic the
natural ECM, creating an artificial ECM that more actively
direct cell growth and differentiation. Biologic cues are
also incorporated into scaffold design in order to mimic
the developmental process to further control cell behavior
and tissue regeneration. These strategies can be utilized
to investigate microenvironmental cues in development and
to maximize scaffold function in tissue engineering and
regenerative medicine.
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